-
公开(公告)号:SG182301A1
公开(公告)日:2012-08-30
申请号:SG2012048567
申请日:2011-01-13
Applicant: UCB PHARMA SA
Inventor: ELLIS MARK , HUMPHREYS DAVID PAUL
Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, 170, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell.
-
公开(公告)号:AU2011206586A1
公开(公告)日:2012-07-19
申请号:AU2011206586
申请日:2011-01-13
Applicant: UCB PHARMA SA
Inventor: ELLIS MARK , HUMPHREYS DAVID PAUL
Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a mutant spr protein and wherein the cell comprises a non-recombinant wild-type chromosomal Tsp gene.
-
公开(公告)号:ES2374222T3
公开(公告)日:2012-02-14
申请号:ES06764991
申请日:2006-07-17
Applicant: UCB PHARMA SA
Inventor: HUMPHREYS DAVID PAUL
Abstract: Fragmento de anticuerpo de IgG al que se une una o más moléculas efectoras seleccionadas de un polímero con un peso molecular promedio en el intervalo de 500 Da a 100.000 Da caracterizado porque está ausente el enlace disulfuro entre cadenas nativas entre las regiones constantes de la cadena pesada (CH1) y ligera (CL) y las regiones constantes de la cadena pesada (CH1) y la cadena ligera (CL) están unidas mediante un enlace disulfuro entre cadenas entre un par de cisteínas, modificadas por ingeniería, una en la región constante de la cadena ligera (CL) y la otra en la región constante de la cadena pesada (CH1), en el que el último enlace disulfuro está ampliamente inaccesible para agentes reductores y moléculas efectoras, de tal manera que permanece intacto durante la unión a molécula efectora y en el que la posición del par de cisteínas, modificadas por ingeniería, se selecciona de la posición 116 de la cadena ligera y 138 de la cadena pesada, la posición 119 de la cadena ligera y 128 de la cadena pesada o la posición 210 de la cadena ligera y 129 de la cadena pesada (numeración de Kabat).
-
公开(公告)号:CA2774692A1
公开(公告)日:2011-03-31
申请号:CA2774692
申请日:2010-09-23
Applicant: UCB PHARMA SA
Inventor: ELLIS MARK , HUMPHREYS DAVID PAUL
Abstract: A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a. a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b. a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c. a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated Deg P gene and optionally a polynucleotide sequence encoding a protein of interest.
-
公开(公告)号:AU2003301318B2
公开(公告)日:2008-09-04
申请号:AU2003301318
申请日:2003-10-15
Applicant: UCB PHARMA SA
Inventor: CHAPMAN ANDREW PAUL , HUMPHREYS DAVID PAUL , ROBINSON MARTYN KIM , SPITALI MARIANGELA
IPC: C12N1/20 , C07K14/245 , C12N1/21 , C12N15/31
Abstract: The present invention provides an E. coli host cell expressing a recombinant antibody characterized in that the E. coli host cell has been genetically modified in order to change at least one physical property of one or more E. coli proteins which in the wild type co-purify with said recombinant antibody.
-
公开(公告)号:DE60224930D1
公开(公告)日:2008-03-20
申请号:DE60224930
申请日:2002-07-05
Applicant: UCB PHARMA SA
Inventor: HUMPHREYS DAVID PAUL
IPC: C12N15/09 , C12N15/13 , C07K16/00 , C12N1/21 , C12N9/16 , C12N9/64 , C12N15/34 , C12N15/70 , C12P21/08
Abstract: Expression vectors encoding bacteriophage signal peptides are described. The vectors may be used for the heterologous expression and secretion of polypeptides such as antibodies in bacterial host cells.
-
公开(公告)号:CA2841824C
公开(公告)日:2021-07-13
申请号:CA2841824
申请日:2012-07-13
Applicant: UCB PHARMA SA
Inventor: ELLIS MARK , HUMPHREYS DAVID PAUL
Abstract: The present invention relates to the development of a bacterial periplasmic system for expressing antibodies. Specifically there is provided a recombinant gram-negative bacterial cell comprising: a mutated Tsp gene which is a knockout mutated Tsp gene or which encodes a Tsp protein having reduced protease activity compared to a wild type Tsp gene, a mutated spr gene encoding an spr protein capable of suppressing the growth phenotype of a cell comprising a mutated Tsp phenotype, an expression vector comprising a recombinant polynucleotide encoding DsbC; and one or more polynucleotides encoding an antibody or an antigen binding fragment thereof specifically binding to CD154.
-
公开(公告)号:EA033720B1
公开(公告)日:2019-11-20
申请号:EA201491571
申请日:2013-02-22
Applicant: UCB PHARMA SA
Inventor: HUMPHREYS DAVID PAUL , PETERS SHIRLEY JANE
IPC: C07K16/00
Abstract: Изобретениеотноситсяк асимметричномусмешанномуантителу, содержащемудветяжелыецепиилифрагменттяжелойцепи, каждаяизкоторыхсодержитпоменьшеймеревариабельнуюобласть, шарнирнуюобластьи C1-домен, гдеперваятяжелаяцепьилиеефрагментпринадлежитклассу IgG4 иимеет a) цистеинмежцепочечнойсвязив положении 127 принумерациипосистеменумерации Kabat вдомене C1, замененныйнадругуюаминокислоту; и b) необязательнооднуилинесколькоизаминокислот, расположенныхв верхнейшарнирнойобластии замененныхцистеином, игдевтораятяжелаяцепьилиеефрагментотличаетсятем, чточастьиливсяцепьотличаетсяпоаминокислотнойпоследовательностиотуказаннойпервойтяжелойцепипоменьшеймерев областивневариабельнойобласти (например, вконстантнойобласти), ксоставам, содержащимих, терапевтическомусредству, вкоторомиспользуютсяобаизуказанныхвыше, ик способамполученияантители состава.
-
公开(公告)号:CA2774692C
公开(公告)日:2017-12-19
申请号:CA2774692
申请日:2010-09-23
Applicant: UCB PHARMA SA
Inventor: ELLIS MARK , HUMPHREYS DAVID PAUL
Abstract: A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a. a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b. a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c. a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated Deg P gene and optionally a polynucleotide sequence encoding a protein of interest.
-
公开(公告)号:AU2012307157B2
公开(公告)日:2017-08-03
申请号:AU2012307157
申请日:2012-09-10
Applicant: UCB PHARMA SA
Inventor: HUMPHREYS DAVID PAUL , LIGHTWOOD DANIEL JOHN , TYSON KERRY LOUISE , KNIGHT DAVID EDWARD ORMONDE , HERVE KARINE JEANNINE MADELEINE , COMPSON JOANNE ELIZABETH , PAGE MATTHEW JON TIMOTHY , PAYNE ANDREW CHARLES , FISHER NICOLA LOUISE , MACKENZIE BRENDON , COX MATTHEW
Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of
-
-
-
-
-
-
-
-
-